A series of novel stereochemically pure derivatives of the investigative broad-spectrum anticonvulsant ADD408003 was designed and synthesized. Five-center four-component (U-5C-4CR) and four-center three-component (U-4C-3CR) variants of Ugi reaction were used in the key step of the synthetic pathways. The compounds obtained were evaluated for the anticonvulsant activitiy in the maximal electroshock seizure (MES), subcutaneous Metrazole (scMET) and minimal clonic seizure (6 Hz) animal models of epilepsy. The efficacies of most derivatives in the 6 Hz model of pharmacoresistant partial seizures were markedly higher than in the ‘classical’ MES and scMET models. The most active compounds, (4R,8aR)-3a, and (4S,8aS)-6 displayed median effective doses (ED50) of 47.90 and 126.19 mg/kg, respectively, for the 6 Hz test.
设计并合成了新型广谱抗惊厥药物AD
D408003的一系列立体
化学纯衍
生物。在合成路径的关键步骤中,使用了五中心四组分(U-5C-4CR)和四中心三组分(U-4C-组分的Ugi反应)的变体。获得的化合物在最大电休克发作(
MES)、皮下甲戊二氮(scMET)和最小阵挛发作(6 Hz)的癫痫动物模型中进行了抗惊厥活性评估。大部分衍
生物在耐药性部分发作的6 Hz模型中的疗效明显高于传统的
MES和scMET模型。最活性的化合物,(4R,8aR)-3a和(4S,8aS)-6在6 Hz测试中分别显示出中效剂量(ED50)为47.90和126.19 mg/kg。